Chronotoxicity of Nedaplatin in Rats

References

• Akaza H., Togashi M., Nishio Y., Miki T., Kotake T., Matsumura Y., Yoshida O., Aso Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S urological cancer study group. Cancer Chemother. Pharmacol. 1992; 31(3)187–192
   PubMedGoogle Scholar
• Boughattas N. A., Lévi F., Hecquet B., Lemaigre G., Roulon A., Fournier C., Reinberg A. Circadian time dependence of murine tolerance for carboplatin. Toxicol. Appl. Pharmacol. 1988; 96(2)233–247, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Boughattas N. A., Hecquet B., Fournier C., Bruguerolle B., Trabelsi H., Bouzouita K., Omrane B., Lévi F. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm. Drug Dispos. 1994; 15(9)761–773, [CSA]
   PubMed Web of Science ®Google Scholar
• Boughattas N. A., Lévi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., Mathe G., Reinberg A. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res. 1989; 49(12)3362–3368
   PubMed Web of Science ®Google Scholar
• Boughattas N. A., Lévi F., Fournier C., Hecquet B., Lemaigre G., Roulon A., Mathe G., Reinberg A. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J. Pharmacol. Exp. Ther. 1990; 255(2)672–679
   PubMedGoogle Scholar
• Bruguerolle B. Temporal aspects of drug absorption and drug distribution. Chronopharmacology, B. Lemmer. Marcel Dekker, Inc., New York 1989; pp. 3–13
   Google Scholar
• Chatelut E., Pivot X., Otto J., Chevreau C., Thyss A., Renee N., Milano G., Canal P. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur. J. Cancer. 2000; 36(2)264–269, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Desoize B., Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002; 42(3)317–325, [CSA]
   PubMed Web of Science ®Google Scholar
• Fukuda M., Shinkai T., Eguchi K., Sasaki Y., Tamura T., Ohe Y., Kojima A., Oshita F., Hara K., Saijo N. Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother. Pharmacol. 1990; 26(6)393–396
   PubMed Web of Science ®Google Scholar
• Hrushesky W. J., Lévi F. A., Halberg F., Kennedy B. J. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res. 1982; 42(3)945–949
   PubMedGoogle Scholar
• Kameyama Y., Okazaki N., Nakagawa M., Koshida H., Nakamura M., Gemba M. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol. Lett. 1990; 52(1)15–24, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Khattab J., Urba S. G. Chemotherapy in head and neck cancer. Overview of newer agents. Hematol. Oncol. Clin. North Am. 1999; 13(4)753–768, [CSA]
   PubMedGoogle Scholar
• Kobayashi M., To H., Tokue A., Fujimura A., Kobayashi E. Cisplatin-induced vomiting depends on circadian timing. Chronobiol. Int. 2001; 18(5)851–863, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kobayashi M., To H., Yuzawa M., Hakamata Y., Higuchi S., Tokue A., Fujimura A., Kobayashi E. Effects of dosing time and schedule on cisplatin-induced nephrotoxicity in rats. J. Pharm. Pharmacol. 2000; 52(10)1233–1237, [CROSSREF]
   PubMedGoogle Scholar
• Labrecque G., Bélanger P. M., Doré F. M., Lalande M. 24-h variations in the distribution of labeled microsheres to the intestine, liver and kidneys. Ann Rev Chronopharmacol., A. Reinberg, M. Smolensky, G. Labrecque. Pergamon Press, Oxford 1988; Vol. 5: pp. 445–448
   Google Scholar
• Leibbrandt M. E., Wolfgang G. H. Differential toxicity of cisplatin, carboplatin, and CI-973 correlates with cellular platinum levels in rat renal cortical slices. Toxicol. Appl. Pharmacol. 1995; 132(2)245–252, [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Lévi F. From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 2002; 19(1)1–19, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Misset J. L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997; 350(9079)681–686, [CSA]
   Google Scholar
• Lévi F. A., Hrushesky W. J., Blomquist C. H., Lakatua D. J., Haus E., Halberg F., Kennedy B. J. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982; 42(3)950–955
   PubMedGoogle Scholar
• Sugeno K., Mizojiri K., Okabe H., Esumi Y., Takaichi M., Okada Y. Studies on the disposition of a new antineoplastic agent, cis-diammine(glycolato)platinum (254-S) (I). Distribution and excretion of platinum in rats. Iyakuhin. Kenkyu. 1991; 22(2)231–242
   Google Scholar
• Touitou Y., Portaluppi F., Smolensky M. H., Rensing L. Ethical Principles and standards for the conduct of human and animal biological rhythm research. Chronobiol. Int. 2004; 21(1)161–170, [CROSSREF]
   PubMed Web of Science ®Google Scholar